uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q2.1956 | Q2 | What is the allele frequency of the SNP rs77168471 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs77168471 has an effect allele G frequency of 0.0354 and non-effect allele A frequency of 0.9646. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs77168471"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7642436', 'SNP': 'rs77168471', 'effect_allele': 'G', 'effect_allele_frequency': 0.0353999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9646000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.1657 | Q2 | What is the allele frequency of the SNP rs115014884 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs115014884 has an effect allele T frequency of 0.0117 and non-effect allele C frequency of 0.9883. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs115014884"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6444116', 'SNP': 'rs115014884', 'effect_allele': 'T', 'effect_allele_frequency': 0.0117, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9883}] | general | Calculate, Select | Allele Frequency |
Q2.613 | Q2 | What is the allele frequency of the SNP rs16922090 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs16922090 has an effect allele G frequency of 0.0909 and non-effect allele A frequency of 0.9091. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs16922090"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_2303002', 'SNP': 'rs16922090', 'effect_allele': 'G', 'effect_allele_frequency': 0.0908999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9091000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.183 | Q2 | What is the allele frequency of the SNP rs10489980 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs10489980 has an effect allele C frequency of 0.3913 and non-effect allele G frequency of 0.6087. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs10489980"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_707870', 'SNP': 'rs10489980', 'effect_allele': 'C', 'effect_allele_frequency': 0.3913, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.6087}] | general | Calculate, Select | Allele Frequency |
Q2.305 | Q2 | What is the allele frequency of the SNP rs2124969 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs2124969 has an effect allele C frequency of 0.3890 and non-effect allele T frequency of 0.6110. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs2124969"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1126628', 'SNP': 'rs2124969', 'effect_allele': 'C', 'effect_allele_frequency': 0.389, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.611}] | general | Calculate, Select | Allele Frequency |
Q2.502 | Q2 | What is the allele frequency of the SNP rs60027946 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs60027946 has an effect allele G frequency of 0.3973 and non-effect allele T frequency of 0.6027. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs60027946"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1796359', 'SNP': 'rs60027946', 'effect_allele': 'G', 'effect_allele_frequency': 0.3973, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.6027}] | general | Calculate, Select | Allele Frequency |
Q2.1696 | Q2 | What is the allele frequency of the SNP rs6805627 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs6805627 has an effect allele C frequency of 0.1357 and non-effect allele G frequency of 0.8643. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs6805627"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6652410', 'SNP': 'rs6805627', 'effect_allele': 'C', 'effect_allele_frequency': 0.1357, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.8643000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.1721 | Q2 | What is the allele frequency of the SNP rs2003343 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs2003343 has an effect allele A frequency of 0.0099 and non-effect allele G frequency of 0.9901. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs2003343"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6715733', 'SNP': 'rs2003343', 'effect_allele': 'A', 'effect_allele_frequency': 0.0099, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9901}] | general | Calculate, Select | Allele Frequency |
Q2.1662 | Q2 | What is the allele frequency of the SNP rs34961808 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs34961808 has an effect allele A frequency of 0.0788 and non-effect allele T frequency of 0.9212. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs34961808"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6462699', 'SNP': 'rs34961808', 'effect_allele': 'A', 'effect_allele_frequency': 0.0788, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9212}] | general | Calculate, Select | Allele Frequency |
Q2.1639 | Q2 | What is the allele frequency of the SNP rs41279908 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs41279908 has an effect allele A frequency of 0.1148 and non-effect allele G frequency of 0.8852. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs41279908"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6366179', 'SNP': 'rs41279908', 'effect_allele': 'A', 'effect_allele_frequency': 0.1148, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.8852}] | general | Calculate, Select | Allele Frequency |
Q2.523 | Q2 | What is the allele frequency of the SNP rs7799403 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs7799403 has an effect allele G frequency of 0.3564 and non-effect allele C frequency of 0.6436. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs7799403"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1887270', 'SNP': 'rs7799403', 'effect_allele': 'G', 'effect_allele_frequency': 0.3564, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.6436}] | general | Calculate, Select | Allele Frequency |
Q2.1985 | Q2 | What is the allele frequency of the SNP rs4424040 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs4424040 has an effect allele G frequency of 0.0477 and non-effect allele A frequency of 0.9523. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs4424040"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7723605', 'SNP': 'rs4424040', 'effect_allele': 'G', 'effect_allele_frequency': 0.0476999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9523000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.1078 | Q2 | What is the allele frequency of the SNP rs1554009 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs1554009 has an effect allele G frequency of 0.3380 and non-effect allele A frequency of 0.6620. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs1554009"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_4157542', 'SNP': 'rs1554009', 'effect_allele': 'G', 'effect_allele_frequency': 0.3379999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.6620000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.482 | Q2 | What is the allele frequency of the SNP rs41529545 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs41529545 has an effect allele C frequency of 0.0424 and non-effect allele A frequency of 0.9576. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs41529545"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1709708', 'SNP': 'rs41529545', 'effect_allele': 'C', 'effect_allele_frequency': 0.0423999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9576000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.160 | Q2 | What is the allele frequency of the SNP rs6976083 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs6976083 has an effect allele T frequency of 0.3444 and non-effect allele G frequency of 0.6556. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs6976083"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_598856', 'SNP': 'rs6976083', 'effect_allele': 'T', 'effect_allele_frequency': 0.3444, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.6556}] | general | Calculate, Select | Allele Frequency |
Q2.1253 | Q2 | What is the allele frequency of the SNP rs12466041 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs12466041 has an effect allele T frequency of 0.0408 and non-effect allele C frequency of 0.9592. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs12466041"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_4892800', 'SNP': 'rs12466041', 'effect_allele': 'T', 'effect_allele_frequency': 0.0408, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9592}] | general | Calculate, Select | Allele Frequency |
Q2.1205 | Q2 | What is the allele frequency of the SNP rs12671012 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs12671012 has an effect allele A frequency of 0.0661 and non-effect allele G frequency of 0.9339. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs12671012"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_4694579', 'SNP': 'rs12671012', 'effect_allele': 'A', 'effect_allele_frequency': 0.0661, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9339}] | general | Calculate, Select | Allele Frequency |
Q2.17 | Q2 | What is the allele frequency of the SNP rs7330113 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs7330113 has an effect allele A frequency of 0.1762 and non-effect allele G frequency of 0.8238. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs7330113"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_62844', 'SNP': 'rs7330113', 'effect_allele': 'A', 'effect_allele_frequency': 0.1762, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.8238}] | general | Calculate, Select | Allele Frequency |
Q2.1550 | Q2 | What is the allele frequency of the SNP rs2322964 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs2322964 has an effect allele C frequency of 0.3625 and non-effect allele G frequency of 0.6375. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs2322964"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_5963326', 'SNP': 'rs2322964', 'effect_allele': 'C', 'effect_allele_frequency': 0.3625, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.6375}] | general | Calculate, Select | Allele Frequency |
Q2.1081 | Q2 | What is the allele frequency of the SNP rs7572368 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs7572368 has an effect allele C frequency of 0.1335 and non-effect allele A frequency of 0.8665. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs7572368"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_4167672', 'SNP': 'rs7572368', 'effect_allele': 'C', 'effect_allele_frequency': 0.1334999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.8665}] | general | Calculate, Select | Allele Frequency |
Q2.1972 | Q2 | What is the allele frequency of the SNP rs60276348 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs60276348 has an effect allele T frequency of 0.1487 and non-effect allele C frequency of 0.8513. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs60276348"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7694955', 'SNP': 'rs60276348', 'effect_allele': 'T', 'effect_allele_frequency': 0.1487, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.8513}] | general | Calculate, Select | Allele Frequency |
Q2.552 | Q2 | What is the allele frequency of the SNP rs12148129 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs12148129 has an effect allele G frequency of 0.0460 and non-effect allele T frequency of 0.9540. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs12148129"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_2011908', 'SNP': 'rs12148129', 'effect_allele': 'G', 'effect_allele_frequency': 0.046, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.954}] | general | Calculate, Select | Allele Frequency |
Q2.1554 | Q2 | What is the allele frequency of the SNP rs7894799 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs7894799 has an effect allele C frequency of 0.4678 and non-effect allele T frequency of 0.5322. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs7894799"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_5987165', 'SNP': 'rs7894799', 'effect_allele': 'C', 'effect_allele_frequency': 0.4678, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.5322}] | general | Calculate, Select | Allele Frequency |
Q2.665 | Q2 | What is the allele frequency of the SNP rs35447393 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs35447393 has an effect allele A frequency of 0.0210 and non-effect allele C frequency of 0.9790. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs35447393"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_2533259', 'SNP': 'rs35447393', 'effect_allele': 'A', 'effect_allele_frequency': 0.021, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.979}] | general | Calculate, Select | Allele Frequency |
Q2.1626 | Q2 | What is the allele frequency of the SNP rs11939851 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs11939851 has an effect allele A frequency of 0.2186 and non-effect allele G frequency of 0.7814. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs11939851"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6333390', 'SNP': 'rs11939851', 'effect_allele': 'A', 'effect_allele_frequency': 0.2186, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.7814}] | general | Calculate, Select | Allele Frequency |
Q2.1028 | Q2 | What is the allele frequency of the SNP rs149668 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs149668 has an effect allele A frequency of 0.0177 and non-effect allele G frequency of 0.9823. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs149668"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_3999308', 'SNP': 'rs149668', 'effect_allele': 'A', 'effect_allele_frequency': 0.0177, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9823}] | general | Calculate, Select | Allele Frequency |
Q2.1994 | Q2 | What is the allele frequency of the SNP rs146706990 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs146706990 has an effect allele A frequency of 0.0293 and non-effect allele C frequency of 0.9707. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs146706990"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7745045', 'SNP': 'rs146706990', 'effect_allele': 'A', 'effect_allele_frequency': 0.0293, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9707}] | general | Calculate, Select | Allele Frequency |
Q2.1519 | Q2 | What is the allele frequency of the SNP rs4730978 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs4730978 has an effect allele A frequency of 0.1974 and non-effect allele G frequency of 0.8026. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs4730978"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_5860339', 'SNP': 'rs4730978', 'effect_allele': 'A', 'effect_allele_frequency': 0.1974, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.8026}] | general | Calculate, Select | Allele Frequency |
Q2.968 | Q2 | What is the allele frequency of the SNP rs201393564 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs201393564 has an effect allele T frequency of 0.0376 and non-effect allele C frequency of 0.9624. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs201393564"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_3713564', 'SNP': 'rs201393564', 'effect_allele': 'T', 'effect_allele_frequency': 0.0376, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9624}] | general | Calculate, Select | Allele Frequency |
Q2.1883 | Q2 | What is the allele frequency of the SNP rs9931725 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs9931725 has an effect allele C frequency of 0.1918 and non-effect allele T frequency of 0.8082. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs9931725"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7321295', 'SNP': 'rs9931725', 'effect_allele': 'C', 'effect_allele_frequency': 0.1917999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.8082000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.287 | Q2 | What is the allele frequency of the SNP rs2569094 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs2569094 has an effect allele T frequency of 0.4959 and non-effect allele C frequency of 0.5041. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs2569094"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1083575', 'SNP': 'rs2569094', 'effect_allele': 'T', 'effect_allele_frequency': 0.4959, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.5041}] | general | Calculate, Select | Allele Frequency |
Q22.161 | Q22 | What is Amrix? | Amrix, also known generically as Cyclobenzaprine Hydrochloride, was approved by the FDA in 1977 to treat Spasticity, Myalgia, Muscle spasm, spinal cord disease, and cerebral palsy. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amrix%" OR LOWER(tradeNames_string) LIKE "%amrix%" OR LOWER(drugSynonyms_string) LIKE "%amrix%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5142', 'tradeNames_string': 'Amrix, Cyclobenzaprine hydrochloride, Flexeril', 'drugName': 'Cyclobenzaprine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Cerebral Palsy (EFO_1000632), Spinal Cord Disease (EFO_0009488), Migraine Disorder (MONDO_0005277), Muscle Spasm (HP_0003394), Spasticity (HP_0001257), Myalgia (HP_0003326)', 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1977, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5143', 'tradeNames_string': 'Amrix, Cyclobenzaprine hydrochloride, Flexeril', 'drugName': 'Cyclobenzaprine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2c (5-HT2c) receptor antagonist', 'linkedDiseasesDrug_string': 'Cerebral Palsy (EFO_1000632), Spinal Cord Disease (EFO_0009488), Migraine Disorder (MONDO_0005277), Muscle Spasm (HP_0003394), Spasticity (HP_0001257), Myalgia (HP_0003326)', 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1977, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.506 | Q22 | What is Signifor Lar Kit? | Signifor Lar Kit, also known generically as Pasireotide Pamoate, was approved by the FDA in 2014 to treat acromegaly. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%signifor lar kit%" OR LOWER(tradeNames_string) LIKE "%signifor lar kit%" OR LOWER(drugSynonyms_string) LIKE "%signifor lar kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6120', 'tradeNames_string': 'Signifor lar, Signifor lar kit', 'drugName': 'Pasireotide Pamoate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Somatostatin receptor 3 agonist', 'linkedDiseasesDrug_string': 'Acromegaly (EFO_1001485)', 'newLinkedTargets_string': 'SSTR3 (ENSG00000278195), SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR1 (ENSG00000139874)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6121', 'tradeNames_string': 'Signifor lar, Signifor lar kit', 'drugName': 'Pasireotide Pamoate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Somatostatin receptor 5 agonist', 'linkedDiseasesDrug_string': 'Acromegaly (EFO_1001485)', 'newLinkedTargets_string': 'SSTR3 (ENSG00000278195), SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR1 (ENSG00000139874)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6122', 'tradeNames_string': 'Signifor lar, Signifor lar kit', 'drugName': 'Pasireotide Pamoate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Somatostatin receptor 1 agonist', 'linkedDiseasesDrug_string': 'Acromegaly (EFO_1001485)', 'newLinkedTargets_string': 'SSTR3 (ENSG00000278195), SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR1 (ENSG00000139874)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6123', 'tradeNames_string': 'Signifor lar, Signifor lar kit', 'drugName': 'Pasireotide Pamoate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Somatostatin receptor 2 agonist', 'linkedDiseasesDrug_string': 'Acromegaly (EFO_1001485)', 'newLinkedTargets_string': 'SSTR3 (ENSG00000278195), SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR1 (ENSG00000139874)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.402 | Q22 | What is Qmiiz Odt? | Qmiiz Odt, also known generically as Meloxicam, was approved by the FDA in 2000 to treat rheumatoid arthritis, juvenile idiopathic arthritis, rheumatic disease, and osteoarthritis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qmiiz odt%" OR LOWER(tradeNames_string) LIKE "%qmiiz odt%" OR LOWER(drugSynonyms_string) LIKE "%qmiiz odt%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_988', 'tradeNames_string': 'Anjeso, Meloxicam, Mobic, Qmiiz odt, Vivlodex', 'drugName': 'Meloxicam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase-2 inhibitor', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Rheumatic Disease (EFO_0005755), Pharyngitis (MONDO_0002258), Osteoarthritis (MONDO_0005178), Juvenile Idiopathic Arthritis (EFO_0002609), Ankylosing Spondylitis (EFO_0003898), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Tuberculosis (MONDO_0018076), Dysmenorrhea (HP_0100607), Systemic Lupus Erythematosus (MONDO_0007915), Shoulder Pain (HP_0030834), Low Back Pain (HP_0003419), Rheumatoid Arthritis (EFO_0000685), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.158 | Q22 | What is Eucrisa? | Eucrisa, also known generically as Crisaborole, was approved by the FDA in 2016 to treat Eczema and atopic eczema. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eucrisa%" OR LOWER(tradeNames_string) LIKE "%eucrisa%" OR LOWER(drugSynonyms_string) LIKE "%eucrisa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5927', 'tradeNames_string': 'Eucrisa', 'drugName': 'Crisaborole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 4 inhibitor', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Psoriasis (EFO_0000676), Localised Scleroderma (EFO_1001361), Vitiligo (EFO_0004208), Alopecia Areata (EFO_0004192), Atopic Eczema (EFO_0000274), Dermatitis (MONDO_0002406)', 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2016, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.326 | Q22 | What is Nourianz? | Nourianz, also known generically as Istradefylline, was approved by the FDA in 2019 to treat Parkinson disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nourianz%" OR LOWER(tradeNames_string) LIKE "%nourianz%" OR LOWER(drugSynonyms_string) LIKE "%nourianz%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2983', 'tradeNames_string': 'Nourianz', 'drugName': 'Istradefylline', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adenosine A2a receptor antagonist', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180), Liver Disease (EFO_0001421), Drug Dependence (EFO_0003890), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'newLinkedTargets_string': 'ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.216 | Q22 | What is Promacta Kit? | Promacta Kit, also known generically as Eltrombopag Olamine, was approved by the FDA in 2008 to treat Thrombocytopenia, chronic hepatitis C virus infection, severe aplastic anemia, and autoimmune thrombocytopenic purpura. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%promacta kit%" OR LOWER(tradeNames_string) LIKE "%promacta kit%" OR LOWER(drugSynonyms_string) LIKE "%promacta kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2769', 'tradeNames_string': 'Promacta, Promacta kit', 'drugName': 'Eltrombopag Olamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thrombopoietin receptor agonist', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Severe Aplastic Anemia (EFO_0006927), Chronic Hepatitis C Virus Infection (EFO_0004220), Myelodysplastic Syndrome (EFO_0000198)', 'newLinkedTargets_string': 'MPL (ENSG00000117400)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.238 | Q22 | What is Imvexxy? | Imvexxy, also known generically as Estradiol, was approved by the FDA in 1975 to treat Premature ovarian insufficiency, Dyspareunia, and hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%imvexxy%" OR LOWER(tradeNames_string) LIKE "%imvexxy%" OR LOWER(drugSynonyms_string) LIKE "%imvexxy%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6277', 'tradeNames_string': 'Adgyn estro, Alora, Aquagen, Bedol, Climara, Climara Pro, Dermestril 100, Dermestril 25, Dermestril 50, Dermestril septem 25, Dermestril septem 50, Dermestril septem 75, Divigel, E-Cypionate, Elestrim, Elestrin, Elleste solo, Elleste solo mx 40, Elleste solo mx 80, Esclim, Estrace, Estraderm, Estraderm mx 100, Estraderm mx 25, Estraderm mx 50, Estraderm mx 75, Estraderm tts 100, Estraderm tts 25, Estraderm tts 50, Estradiol, Estrasorb, Estring, Estrogel, Evamist, Evorel 100, Evorel 25, Evorel 50, Evorel 75, Fematrix 40, Fematrix 80, Fempatch, Femseven 100, Femseven 50, Femseven 75, Gvnodiol, Gynodiol, Gynogen, Imvexxy, Innofem, Menorest 37.5, Menorest 50, Menorest 75, Menoring 50, Menostar, Minivelle, Oestradiol, Progynova ts, Sandrena, Vagifem, Vagifem 18, Vagifem 8, Vivelle, Vivelle-dot, Zumenon', 'drugName': 'Estradiol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Estrogen receptor alpha agonist', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Migraine Disorder (MONDO_0005277), Dysmenorrhea (HP_0100607), Obesity (EFO_0001073), Dry Eye Syndrome (EFO_1000906), Atherosclerosis (EFO_0003914), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Hot Flashes (HP_0031217), Prostate Carcinoma (EFO_0001663), Breast Carcinoma (EFO_0000305), Myocardial Ischemia (EFO_1001375), Post-Traumatic Stress Disorder (EFO_0001358), Osteoporosis (EFO_0003882), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Breast Cancer (MONDO_0007254), Polycystic Ovary Syndrome (EFO_0000660), Osteopenia (HP_0000938), Postpartum Depression (EFO_0007453), Premature Ovarian Insufficiency (HP_0008209), Schizoaffective Disorder (EFO_0005411), Non-Alcoholic Steatohepatitis (EFO_1001249), Endometriosis (EFO_0001065), Amenorrhea (EFO_0010269), Sexual Dysfunction (EFO_0004714), Postmenopausal Atrophic Vaginitis (MONDO_0001410), Hypogonadism (MONDO_0002146), Turner Syndrome (MONDO_0019499), Menopause (EFO_0003922), Infertility (EFO_0000545), Urinary Tract Infection (EFO_0003103), Carcinoid Tumor (EFO_0004243), Hiv-1 Infection (EFO_0000180), Depressive Disorder (MONDO_0002050), Hiv Infection (EFO_0000764), Type 2 Diabetes Mellitus (MONDO_0005148), Atrophic Vaginitis (EFO_1001271), Blood Coagulation Disease (EFO_0009314), Atrophy (EFO_1000096), Bulimia Nervosa (EFO_0005204), Type 1 Diabetes Mellitus (MONDO_0005147), Dyspareunia (HP_0030016), Schizophrenia (MONDO_0005090), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.293 | Q22 | What is Vyondys 53? | Vyondys 53, also known generically as Golodirsen, was approved by the FDA in 2019 to treat Duchenne muscular dystrophy and muscular dystrophy. It is a oligonucleotide therapy that acts as a(n) positive modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vyondys 53%" OR LOWER(tradeNames_string) LIKE "%vyondys 53%" OR LOWER(drugSynonyms_string) LIKE "%vyondys 53%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4074', 'tradeNames_string': 'Vyondys 53', 'drugName': 'Golodirsen', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'positive modulator', 'drugMechanismOfAction': 'Dystrophin pre-mRNA positive modulator', 'linkedDiseasesDrug_string': 'Muscular Dystrophy (MONDO_0020121), Duchenne Muscular Dystrophy (MONDO_0010679)', 'newLinkedTargets_string': 'DMD (ENSG00000198947)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.304 | Q22 | What is Hysingla Er? | Hysingla Er, also known generically as Hydrocodone Bitartrate, was approved by the FDA in 1943 to treat pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hysingla er%" OR LOWER(tradeNames_string) LIKE "%hysingla er%" OR LOWER(drugSynonyms_string) LIKE "%hysingla er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2476', 'tradeNames_string': 'Dicodid, Hysingla, Hysingla er, Mercodinone, Vantrela er, Zohydro er', 'drugName': 'Hydrocodone Bitartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta agonist', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890), Osteoarthritis (MONDO_0005178), Rotator Cuff Tear (EFO_1001250), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Kidney Disease (EFO_0003086), Injury (EFO_0000546), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1943, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.362 | Q22 | What is Liletta? | Liletta, also known generically as Levonorgestrel, was approved by the FDA in 1982 to treat Menorrhagia. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%liletta%" OR LOWER(tradeNames_string) LIKE "%liletta%" OR LOWER(drugSynonyms_string) LIKE "%liletta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2857', 'tradeNames_string': 'Athentia next, Emerres, Emerres una, Ezinelle, Fallback solo, Her style, Isteranda, Jadelle, Jaydess, Kyleena, Levonelle, Levonelle one step, Levonelle-2, Levonorgestrel, Levosert, Liletta, Microval, Mirena, Norgeston, Norplant, Norplant Ii, Norplant System, Opcicon one-step, Ovrette, Plan B, Plan b one-step, Postinor-2, Skyla, Upostelle', 'drugName': 'Levonorgestrel', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Progesterone receptor agonist', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Adenomyosis (EFO_1001757), Menorrhagia (HP_0000132), Osteopenia (HP_0000938), Hiv Infection (EFO_0000764), Chronic Lymphocytic Leukemia (EFO_0000095), Chronic Hepatitis B Virus Infection (EFO_0004239), Hemorrhage (MP_0001914), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Non-Alcoholic Steatohepatitis (EFO_1001249), Dysmenorrhea (HP_0100607), Hiv-1 Infection (EFO_0000180), Endometriosis (EFO_0001065), Chronic Hepatitis C Virus Infection (EFO_0004220), Type 2 Diabetes Mellitus (MONDO_0005148), Anorexia Nervosa (MONDO_0005351)', 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.679 | Q22 | What is Caprelsa? | Caprelsa, also known generically as Vandetanib, was approved by the FDA in 2011 to treat cancer, neoplasm, papillary thyroid carcinoma, thyroid carcinoma, thyroid neoplasm, thyroid cancer, and medullary thyroid gland carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%caprelsa%" OR LOWER(tradeNames_string) LIKE "%caprelsa%" OR LOWER(drugSynonyms_string) LIKE "%caprelsa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1931', 'tradeNames_string': 'Caprelsa, Zactima', 'drugName': 'Vandetanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Ephrin receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1932', 'tradeNames_string': 'Caprelsa, Zactima', 'drugName': 'Vandetanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase TIE-2 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1933', 'tradeNames_string': 'Caprelsa, Zactima', 'drugName': 'Vandetanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase SRC inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1934', 'tradeNames_string': 'Caprelsa, Zactima', 'drugName': 'Vandetanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1935', 'tradeNames_string': 'Caprelsa, Zactima', 'drugName': 'Vandetanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1936', 'tradeNames_string': 'Caprelsa, Zactima', 'drugName': 'Vandetanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1937', 'tradeNames_string': 'Caprelsa, Zactima', 'drugName': 'Vandetanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase BRK inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.334 | Q22 | What is Acuvail? | Acuvail, also known generically as Ketorolac Tromethamine, was approved by the FDA in 1989 to treat Ocular pain, inflammation, pain, and cataract. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acuvail%" OR LOWER(tradeNames_string) LIKE "%acuvail%" OR LOWER(drugSynonyms_string) LIKE "%acuvail%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2258', 'tradeNames_string': 'Acular, Acular ls, Acular preservative free, Acuvail, Ketorolac tromethamine, Sprix, Toradol', 'drugName': 'Ketorolac Tromethamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Heart Disease (EFO_0003777), Cerebral Arterial Disease (EFO_1000859), Pulpitis (EFO_1001139), Cataract (MONDO_0005129), Migraine Disorder (MONDO_0005277), Renal Colic (EFO_1001412), Pain (EFO_0003843), Ocular Pain (HP_0200026), Back Pain (HP_0003418), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Inflammation (MP_0001845), Allergic Rhinitis (EFO_0005854), Shoulder Impingement Syndrome (EFO_1001178), Nephrolithiasis (EFO_0004253), Macular Retinal Edema (MONDO_0003005)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1989, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.202 | Q22 | What is Silenor? | Silenor, also known generically as Doxepin Hydrochloride, was approved by the FDA in 1969 to treat atopic eczema, bipolar disorder, unipolar depression, insomnia, and alcohol dependence. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%silenor%" OR LOWER(tradeNames_string) LIKE "%silenor%" OR LOWER(drugSynonyms_string) LIKE "%silenor%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2495', 'tradeNames_string': 'Adapin, Doxepin hydrochloride, Quitaxon, Silenor, Sinequan, Xepin, Zonalon', 'drugName': 'Doxepin Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Pain (EFO_0003843), Atopic Eczema (EFO_0000274), Bipolar Disorder (MONDO_0004985), Insomnia (EFO_0004698), Oral Mucositis (EFO_1001904), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1969, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.80 | Q22 | What is Nexletol? | Nexletol, also known generically as Bempedoic Acid, was approved by the FDA in 2020 to treat cardiovascular disease, coronary artery disease, atherosclerosis, and familial hypercholesterolemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nexletol%" OR LOWER(tradeNames_string) LIKE "%nexletol%" OR LOWER(drugSynonyms_string) LIKE "%nexletol%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5953', 'tradeNames_string': 'Nexletol', 'drugName': 'Bempedoic Acid', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'ATP-citrate synthase inhibitor', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Coronary Artery Disease (EFO_0001645), Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Disorder Of Lipid Metabolism (Orphanet_309005), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'newLinkedTargets_string': 'ACLY (ENSG00000131473)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.605 | Q22 | What is Tadliq? | Tadliq, also known generically as Tadalafil, was approved by the FDA in 2003 to treat Impotence, benign prostatic hyperplasia, pulmonary arterial hypertension, erectile dysfunction, and pulmonary hypertension. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tadliq%" OR LOWER(tradeNames_string) LIKE "%tadliq%" OR LOWER(drugSynonyms_string) LIKE "%tadliq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1194', 'tradeNames_string': 'Adcirca, Cialis, Tadliq', 'drugName': 'Tadalafil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 5A inhibitor', 'linkedDiseasesDrug_string': 'Eisenmenger Syndrome (EFO_0009200), Erectile Dysfunction (EFO_0004234), Multiple Myeloma (EFO_0001378), Cancer (MONDO_0004992), Pulmonary Hypertension (MONDO_0005149), Obesity (EFO_0001073), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Essential Hypertension (MONDO_0001134), Priapism (HP_0200023), Muscular Dystrophy (MONDO_0020121), Transposition Of The Great Arteries (MONDO_0000153), Gastroparesis (EFO_1000948), Abnormality Of Cardiovascular System Morphology (HP_0030680), Vascular Dementia (EFO_0004718), Anaplastic Astrocytoma (EFO_0002499), Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Glucose Intolerance (HP_0001952), Interstitial Lung Disease (EFO_0004244), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Sexual Dysfunction (EFO_0004714), Pancreatic Carcinoma (EFO_0002618), Cushing Syndrome (EFO_0003099), Insulin Resistance (EFO_0002614), Stroke (EFO_0000712), Benign Prostatic Hyperplasia (EFO_0000284), Duchenne Muscular Dystrophy (MONDO_0010679), Systemic Scleroderma (EFO_0000717), Impotence (HP_0000802), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Raynaud Disease (EFO_1001145), Major Depressive Disorder (MONDO_0002009), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.576 | Q22 | What is Koselugo? | Koselugo, also known generically as Selumetinib Sulfate, was approved by the FDA in 2020 to treat neurofibromatosis and neurofibromatosis type 1. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%koselugo%" OR LOWER(tradeNames_string) LIKE "%koselugo%" OR LOWER(drugSynonyms_string) LIKE "%koselugo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3990', 'tradeNames_string': 'Koselugo', 'drugName': 'Selumetinib Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Astrocytoma (EFO_0000272), Neurofibromatosis (EFO_0008514), Neurofibromatosis Type 1 (MONDO_0018975), Metastatic Melanoma (EFO_0002617), Cutaneous Melanoma (EFO_0000389)', 'newLinkedTargets_string': 'MAP2K2 (ENSG00000126934), MAP2K1 (ENSG00000169032)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.452 | Q22 | What is Nerlynx? | Nerlynx, also known generically as Neratinib Maleate, was approved by the FDA in 2017 to treat breast carcinoma and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nerlynx%" OR LOWER(tradeNames_string) LIKE "%nerlynx%" OR LOWER(drugSynonyms_string) LIKE "%nerlynx%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6198', 'tradeNames_string': 'Nerlynx', 'drugName': 'Neratinib Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-4 inhibitor', 'linkedDiseasesDrug_string': 'Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6199', 'tradeNames_string': 'Nerlynx', 'drugName': 'Neratinib Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor erbB1 inhibitor', 'linkedDiseasesDrug_string': 'Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6200', 'tradeNames_string': 'Nerlynx', 'drugName': 'Neratinib Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-2 inhibitor', 'linkedDiseasesDrug_string': 'Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.513 | Q22 | What is Alimta? | Alimta, also known generically as Pemetrexed, was approved by the FDA in 2004 to treat cancer, mesothelioma, neoplasm, malignant pleural mesothelioma, and malignant peritoneal mesothelioma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alimta%" OR LOWER(tradeNames_string) LIKE "%alimta%" OR LOWER(drugSynonyms_string) LIKE "%alimta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4615', 'tradeNames_string': 'Alimta, Pemfexy', 'drugName': 'Pemetrexed', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dihydrofolate reductase inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Medulloblastoma (EFO_0002939), Thymic Carcinoma (EFO_1000576), Gestational Trophoblastic Neoplasm (MONDO_0018944), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Malignant Peritoneal Mesothelioma (EFO_0005567), Colorectal Neoplasm (EFO_0004142), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Biliary Tract Cancer (MONDO_0003060), Gastric Carcinoma (EFO_0000178), Urethra Cancer (MONDO_0004192), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Bronchoalveolar Adenocarcinoma (EFO_0000308), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Salivary Gland Carcinoma (MONDO_0000521), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Peritoneum Cancer (MONDO_0002087), Large Cell Lung Carcinoma (EFO_0003050), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Leptomeningeal Metastasis (EFO_1001012), Thymoma (EFO_1000581), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Osteosarcoma (EFO_0000637), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Cancer (MONDO_0008903), Chordoma (MONDO_0008978), Sarcoma (EFO_0000691), Nasopharyngeal Neoplasm (EFO_0004252), Malignant Pleural Mesothelioma (EFO_0000770), Stomach Neoplasm (EFO_0003897), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890), DHFR (ENSG00000228716), GART (ENSG00000159131)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4616', 'tradeNames_string': 'Alimta, Pemfexy', 'drugName': 'Pemetrexed', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thymidylate synthase inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Medulloblastoma (EFO_0002939), Thymic Carcinoma (EFO_1000576), Gestational Trophoblastic Neoplasm (MONDO_0018944), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Malignant Peritoneal Mesothelioma (EFO_0005567), Colorectal Neoplasm (EFO_0004142), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Biliary Tract Cancer (MONDO_0003060), Gastric Carcinoma (EFO_0000178), Urethra Cancer (MONDO_0004192), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Bronchoalveolar Adenocarcinoma (EFO_0000308), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Salivary Gland Carcinoma (MONDO_0000521), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Peritoneum Cancer (MONDO_0002087), Large Cell Lung Carcinoma (EFO_0003050), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Leptomeningeal Metastasis (EFO_1001012), Thymoma (EFO_1000581), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Osteosarcoma (EFO_0000637), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Cancer (MONDO_0008903), Chordoma (MONDO_0008978), Sarcoma (EFO_0000691), Nasopharyngeal Neoplasm (EFO_0004252), Malignant Pleural Mesothelioma (EFO_0000770), Stomach Neoplasm (EFO_0003897), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890), DHFR (ENSG00000228716), GART (ENSG00000159131)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4617', 'tradeNames_string': 'Alimta, Pemfexy', 'drugName': 'Pemetrexed', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'GAR transformylase inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Medulloblastoma (EFO_0002939), Thymic Carcinoma (EFO_1000576), Gestational Trophoblastic Neoplasm (MONDO_0018944), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Malignant Peritoneal Mesothelioma (EFO_0005567), Colorectal Neoplasm (EFO_0004142), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Biliary Tract Cancer (MONDO_0003060), Gastric Carcinoma (EFO_0000178), Urethra Cancer (MONDO_0004192), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Bronchoalveolar Adenocarcinoma (EFO_0000308), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Salivary Gland Carcinoma (MONDO_0000521), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Peritoneum Cancer (MONDO_0002087), Large Cell Lung Carcinoma (EFO_0003050), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Leptomeningeal Metastasis (EFO_1001012), Thymoma (EFO_1000581), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Osteosarcoma (EFO_0000637), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Cancer (MONDO_0008903), Chordoma (MONDO_0008978), Sarcoma (EFO_0000691), Nasopharyngeal Neoplasm (EFO_0004252), Malignant Pleural Mesothelioma (EFO_0000770), Stomach Neoplasm (EFO_0003897), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890), DHFR (ENSG00000228716), GART (ENSG00000159131)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3690', 'tradeNames_string': 'Alimta', 'drugName': 'Pemetrexed Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dihydrofolate reductase inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Gestational Trophoblastic Neoplasm (MONDO_0018944), Thymic Carcinoma (EFO_1000576), Urothelial Carcinoma (EFO_0008528), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Urethra Cancer (MONDO_0004192), Bronchoalveolar Adenocarcinoma (EFO_0000308), Metastasis (EFO_0009708), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Large Cell Lung Carcinoma (EFO_0003050), Lung Neoplasm (MONDO_0021117), Peritoneum Cancer (MONDO_0002087), Cervical Cancer (MONDO_0002974), Thymoma (EFO_1000581), Head And Neck Malignant Neoplasia (EFO_0006859), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890), DHFR (ENSG00000228716), GART (ENSG00000159131)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3691', 'tradeNames_string': 'Alimta', 'drugName': 'Pemetrexed Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thymidylate synthase inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Gestational Trophoblastic Neoplasm (MONDO_0018944), Thymic Carcinoma (EFO_1000576), Urothelial Carcinoma (EFO_0008528), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Urethra Cancer (MONDO_0004192), Bronchoalveolar Adenocarcinoma (EFO_0000308), Metastasis (EFO_0009708), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Large Cell Lung Carcinoma (EFO_0003050), Lung Neoplasm (MONDO_0021117), Peritoneum Cancer (MONDO_0002087), Cervical Cancer (MONDO_0002974), Thymoma (EFO_1000581), Head And Neck Malignant Neoplasia (EFO_0006859), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890), DHFR (ENSG00000228716), GART (ENSG00000159131)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3692', 'tradeNames_string': 'Alimta', 'drugName': 'Pemetrexed Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'GAR transformylase inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Gestational Trophoblastic Neoplasm (MONDO_0018944), Thymic Carcinoma (EFO_1000576), Urothelial Carcinoma (EFO_0008528), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Urethra Cancer (MONDO_0004192), Bronchoalveolar Adenocarcinoma (EFO_0000308), Metastasis (EFO_0009708), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Large Cell Lung Carcinoma (EFO_0003050), Lung Neoplasm (MONDO_0021117), Peritoneum Cancer (MONDO_0002087), Cervical Cancer (MONDO_0002974), Thymoma (EFO_1000581), Head And Neck Malignant Neoplasia (EFO_0006859), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890), DHFR (ENSG00000228716), GART (ENSG00000159131)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.633 | Q22 | What is Xyosted (Autoinjector)? | Xyosted (Autoinjector), also known generically as Testosterone Enanthate, was approved by the FDA in 1953 to treat Hypogonadotropic hypogonadism and hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xyosted (autoinjector)%" OR LOWER(tradeNames_string) LIKE "%xyosted (autoinjector)%" OR LOWER(drugSynonyms_string) LIKE "%xyosted (autoinjector)%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5959', 'tradeNames_string': 'Delatestryl, Primoteston depot, Testosterone enanthate, Xyosted (autoinjector)', 'drugName': 'Testosterone Enanthate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Prostate Cancer (MONDO_0008315), Hypogonadotropic Hypogonadism (HP_0000044), Metastatic Prostate Cancer (EFO_0000196), Chronic Obstructive Pulmonary Disease (EFO_0000341), Weight Loss (HP_0001824), Hiv Wasting Syndrome (EFO_0007312), Facioscapulohumeral Dystrophy (Orphanet_269), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1953, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.610 | Q22 | What is Talzenna? | Talzenna, also known generically as Talazoparib Tosylate, was approved by the FDA in 2018 to treat breast carcinoma, breast neoplasm, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%talzenna%" OR LOWER(tradeNames_string) LIKE "%talzenna%" OR LOWER(drugSynonyms_string) LIKE "%talzenna%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2224', 'tradeNames_string': 'Talzenna', 'drugName': 'Talazoparib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Poly [ADP-ribose] polymerase-1 inhibitor', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Triple-Negative Breast Cancer (EFO_0005537), Acute Myeloid Leukemia (EFO_0000222), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'PARP2 (ENSG00000129484), PARP1 (ENSG00000143799)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2225', 'tradeNames_string': 'Talzenna', 'drugName': 'Talazoparib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Poly [ADP-ribose] polymerase 2 inhibitor', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Triple-Negative Breast Cancer (EFO_0005537), Acute Myeloid Leukemia (EFO_0000222), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'PARP2 (ENSG00000129484), PARP1 (ENSG00000143799)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.366 | Q22 | What is Levolet? | Levolet, also known generically as Levothyroxine Sodium, was approved by the FDA in 2000 to treat thyroid carcinoma, hypothyroidism, differentiated thyroid carcinoma, thyroid cancer, and congenital hypothyroidism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levolet%" OR LOWER(tradeNames_string) LIKE "%levolet%" OR LOWER(drugSynonyms_string) LIKE "%levolet%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5964', 'tradeNames_string': 'Eltroxin, Ermeza, Euthyrox, Evotrox, L-thyroxine henning, Levo-t, Levolet, Levothroid, Levothyroid, Levothyroxine sodium, Levoxine, Levoxyl, Novothyrox, Soloxine, Synthroid, Thyquidity, Thyro-tabs, Thyrol L, Thyroxine, Tirosint, Tirosint-sol, Unithroid', 'drugName': 'Levothyroxine Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Congenital Hypothyroidism (MONDO_0018612), Pain (EFO_0003843), Thyroid Carcinoma (EFO_0002892), Thyroid Cancer (MONDO_0002108), Bipolar Disorder (MONDO_0004985), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017)', 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.344 | Q22 | What is Revlimid? | Revlimid, also known generically as Lenalidomide, was approved by the FDA in 2005 to treat myelodysplastic syndrome, immune system disease, multiple myeloma, anemia (phenotype), Mantle cell lymphoma, and anemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%revlimid%" OR LOWER(tradeNames_string) LIKE "%revlimid%" OR LOWER(drugSynonyms_string) LIKE "%revlimid%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_456', 'tradeNames_string': 'Revlimid', 'drugName': 'Lenalidomide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'CRL4(CRBN) E3 ubiquitin ligase inhibitor', 'linkedDiseasesDrug_string': "Autism (EFO_0003758), Multiple Myeloma (EFO_0001378), Essential Thrombocythemia (EFO_0000479), Malignant Colon Neoplasm (MONDO_0021063), Malignant Glioma (MONDO_0100342), Anemia (Phenotype) (EFO_0004272), Hiv-1 Infection (EFO_0000180), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Al Amyloidosis (MONDO_0019438), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Anemia (MONDO_0002280), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Marginal Zone B-Cell Lymphoma (EFO_1000630), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Rectum Cancer (EFO_1000657), Prolymphocytic Leukemia (MONDO_0001023), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Hiv Infection (EFO_0000764), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Radiculopathy (MONDO_0002959), Sinus Histiocytosis With Massive Lymphadenopathy (MONDO_0006412), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Asymptomatic Myeloma (EFO_0003073), Primary Myelofibrosis (EFO_0002430), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Plasmacytoma (EFO_0006738), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Cachexia (HP_0004326), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Neoplasm Of Mature B-Cells (EFO_0000096), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Metastatic Prostate Cancer (EFO_0000196), Primary Systemic Amyloidosis (MONDO_0017816), Epstein-Barr Virus Infection (EFO_0000769), Complex Regional Pain Syndrome (EFO_1001998), Thyroid Carcinoma (EFO_0002892), Graft Versus Host Disease (MONDO_0013730), Burkitts Lymphoma (EFO_0000309), Plasma Cell Leukemia (EFO_0006475), B-Cell Neoplasm (MONDO_0004095), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Colorectal Neoplasm (EFO_0004142), Chronic Myelomonocytic Leukemia (EFO_1001779), Immune System Disease (EFO_0000540), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Renal Cell Carcinoma (EFO_0000681), Poems Syndrome (EFO_1001115), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Bladder Tumor (EFO_0000294)", 'newLinkedTargets_string': 'CRBN (ENSG00000113851), DDB1 (ENSG00000167986), CUL4A (ENSG00000139842), RBX1 (ENSG00000100387)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.675 | Q22 | What is Ukoniq? | Ukoniq, also known generically as Umbralisib Tosylate, was approved by the FDA in 2021 to treat marginal zone B-cell lymphoma and follicular lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ukoniq%" OR LOWER(tradeNames_string) LIKE "%ukoniq%" OR LOWER(drugSynonyms_string) LIKE "%ukoniq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3011', 'tradeNames_string': 'Ukoniq', 'drugName': 'Umbralisib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Casein kinase I epsilon inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Rectum Cancer (EFO_1000657), Diffuse Large B-Cell Lymphoma (EFO_0000403), Follicular Lymphoma (MONDO_0018906), Chronic Lymphocytic Leukemia (EFO_0000095), Esophageal Cancer (MONDO_0007576), Mantle Cell Lymphoma (EFO_1001469), Myelofibrosis (MONDO_0044903), Gastrointestinal Stromal Tumor (MONDO_0011719), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Gastric Cancer (MONDO_0001056), Hodgkins Lymphoma (EFO_0000183), Marginal Zone B-Cell Lymphoma (EFO_1000630)', 'newLinkedTargets_string': 'CSNK1E (ENSG00000213923), PIK3CD (ENSG00000171608), ABL1 (ENSG00000097007)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3012', 'tradeNames_string': 'Ukoniq', 'drugName': 'Umbralisib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PI3-kinase p110-delta subunit inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Rectum Cancer (EFO_1000657), Diffuse Large B-Cell Lymphoma (EFO_0000403), Follicular Lymphoma (MONDO_0018906), Chronic Lymphocytic Leukemia (EFO_0000095), Esophageal Cancer (MONDO_0007576), Mantle Cell Lymphoma (EFO_1001469), Myelofibrosis (MONDO_0044903), Gastrointestinal Stromal Tumor (MONDO_0011719), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Gastric Cancer (MONDO_0001056), Hodgkins Lymphoma (EFO_0000183), Marginal Zone B-Cell Lymphoma (EFO_1000630)', 'newLinkedTargets_string': 'CSNK1E (ENSG00000213923), PIK3CD (ENSG00000171608), ABL1 (ENSG00000097007)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3013', 'tradeNames_string': 'Ukoniq', 'drugName': 'Umbralisib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Rectum Cancer (EFO_1000657), Diffuse Large B-Cell Lymphoma (EFO_0000403), Follicular Lymphoma (MONDO_0018906), Chronic Lymphocytic Leukemia (EFO_0000095), Esophageal Cancer (MONDO_0007576), Mantle Cell Lymphoma (EFO_1001469), Myelofibrosis (MONDO_0044903), Gastrointestinal Stromal Tumor (MONDO_0011719), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Gastric Cancer (MONDO_0001056), Hodgkins Lymphoma (EFO_0000183), Marginal Zone B-Cell Lymphoma (EFO_1000630)', 'newLinkedTargets_string': 'CSNK1E (ENSG00000213923), PIK3CD (ENSG00000171608), ABL1 (ENSG00000097007)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.294 | Q22 | What is Zoladex? | Zoladex, also known generically as Goserelin, was approved by the FDA in 1989 to treat neoplasm. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zoladex%" OR LOWER(tradeNames_string) LIKE "%zoladex%" OR LOWER(drugSynonyms_string) LIKE "%zoladex%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_246', 'tradeNames_string': 'Novgos, Zoladex, Zoladex la', 'drugName': 'Goserelin Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Fallopian Tube Cancer (MONDO_0002158), Menopause (EFO_0003922), Salivary Gland Carcinoma (MONDO_0000521), Infertility (EFO_0000545), Male Breast Carcinoma (EFO_0006861), Metabolic Syndrome (EFO_0000195), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1989, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2259', 'tradeNames_string': 'Zoladex', 'drugName': 'Goserelin', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Uterine Fibroid (EFO_0000731), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Adenomyosis (EFO_1001757), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Premature Ovarian Insufficiency (HP_0008209), Male Breast Carcinoma (EFO_0006861), Endometriosis (EFO_0001065), Menopause (EFO_0003922), Salivary Gland Carcinoma (MONDO_0000521), Infertility (EFO_0000545), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Hodgkins Lymphoma (EFO_0000183), Invasive Lobular Carcinoma (EFO_0000553), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Metabolic Syndrome (EFO_0000195)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1989, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.288 | Q22 | What is Gvoke Hypopen? | Gvoke Hypopen, also known generically as Glucagon, was approved by the FDA in 1998 to treat Hypoglycemia and diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gvoke hypopen%" OR LOWER(tradeNames_string) LIKE "%gvoke hypopen%" OR LOWER(drugSynonyms_string) LIKE "%gvoke hypopen%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1857', 'tradeNames_string': 'Baqsimi, Glucagen Hypokit, Glucagon, Glucagon Emergency Kit, Gvoke hypopen, Gvoke pfs', 'drugName': 'Glucagon', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Common Cold (EFO_0007214), Familial Hyperinsulinism (MONDO_0017182), Obesity (EFO_0001073), Type 1 Diabetes Mellitus (MONDO_0005147), Hypoglycemia (HP_0001943), Type 2 Diabetes Mellitus (MONDO_0005148), Hyperinsulinemic Hypoglycemia (EFO_0007318)', 'newLinkedTargets_string': 'GCGR (ENSG00000215644)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.337 | Q22 | What is Prevacid Iv? | Prevacid Iv, also known generically as Lansoprazole, was approved by the FDA in 1995 to treat Peptic ulcer, gastroesophageal reflux disease, and gastric ulcer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prevacid iv%" OR LOWER(tradeNames_string) LIKE "%prevacid iv%" OR LOWER(drugSynonyms_string) LIKE "%prevacid iv%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2720', 'tradeNames_string': 'Lansoprazole, Opiren, Prevacid, Prevacid 24 hr, Prevacid Delayed Release, Prevacid Solutab, Prevacid iv, Zoton', 'drugName': 'Lansoprazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Potassium-transporting ATPase inhibitor', 'linkedDiseasesDrug_string': 'Chronic Lymphocytic Leukemia (EFO_0000095), Pseudomyxoma Peritonei (EFO_0007456), Pain (EFO_0003843), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Laryngopharyngeal Reflux (EFO_1001355), Peptic Ulcer (HP_0004398), Gastritis (EFO_0000217), Premature Birth (EFO_0003917), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Peptic Esophagitis (EFO_1001095), Gastroesophageal Reflux Disease (EFO_0003948), Cervical Cancer (MONDO_0002974), Gout (EFO_0004274), Rectum Cancer (EFO_1000657), Osteoarthritis (MONDO_0005178), Neoplasm (EFO_0000616), Eosinophilic Esophagitis (EFO_0004232), Cystic Fibrosis (MONDO_0009061), Type 1 Diabetes Mellitus (MONDO_0005147), Helicobacter Pylori Infectious Disease (EFO_1000961)', 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.484 | Q22 | What is Oxtellar Xr? | Oxtellar Xr, also known generically as Oxcarbazepine, was approved by the FDA in 2000 to treat Seizure and epilepsy. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxtellar xr%" OR LOWER(tradeNames_string) LIKE "%oxtellar xr%" OR LOWER(drugSynonyms_string) LIKE "%oxtellar xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1913', 'tradeNames_string': 'Oxcarbazepine, Oxtellar xr, Trileptal', 'drugName': 'Oxcarbazepine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Aggressive Behavior (EFO_0003015), Multiple Sclerosis (MONDO_0005301), Agitation (HP_0000713), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Seizure (HP_0001250), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.55 | Q22 | What is Qulipta? | Qulipta, also known generically as Atogepant, was approved by the FDA in 2021 to treat migraine disorder. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qulipta%" OR LOWER(tradeNames_string) LIKE "%qulipta%" OR LOWER(drugSynonyms_string) LIKE "%qulipta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2683', 'tradeNames_string': 'Qulipta', 'drugName': 'Atogepant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Calcitonin gene-related peptide type 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'newLinkedTargets_string': 'CALCRL (ENSG00000064989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.252 | Q22 | What is Fenoglide? | Fenoglide, also known generically as Fenofibrate, was approved by the FDA in 1993 to treat Abnormal circulating lipid concentration, Hypercholesterolemia, cardiovascular disease, diabetes mellitus, hypothyroidism, and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fenoglide%" OR LOWER(tradeNames_string) LIKE "%fenoglide%" OR LOWER(drugSynonyms_string) LIKE "%fenoglide%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1497', 'tradeNames_string': 'Antara, Antara (micronized), Fenofibrate, Fenofibrate (micronized), Fenogal, Fenoglide, Lipantil, Lipantil micro 200, Lipantil micro 267, Lipantil micro 67, Lipidil, Lipofen, Supralip 160, Tricor, Tricor (micronized), Triglide', 'drugName': 'Fenofibrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor alpha agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Coronary Artery Disease (EFO_0001645), Multiple Myeloma (EFO_0001378), Combined Hyperlipidemia (Orphanet_79211), Obesity (EFO_0001073), Hypothyroidism (EFO_0004705), Metabolic Disease (EFO_0000589), Primary Biliary Cirrhosis (EFO_1001486), Diabetic Retinopathy (EFO_0003770), Huntington Disease (MONDO_0007739), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Non-Alcoholic Steatohepatitis (EFO_1001249), Disorder Of Lipid Metabolism (Orphanet_309005), Abnormal Circulating Lipid Concentration (HP_0003119), Hypercholesterolemia (HP_0003124), Hiv-1 Infection (EFO_0000180), Hyperlipoproteinemia (MONDO_0037748), Alcohol Dependence (MONDO_0007079), Hyperlipoproteinemia Type 3 (MONDO_0018473), Lipodystrophy (EFO_1000727), Diabetic Nephropathy (EFO_0000401), Burn (EFO_0009516), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), Sclerosing Cholangitis (EFO_0004268)', 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.227 | Q22 | What is Balversa? | Balversa, also known generically as Erdafitinib, was approved by the FDA in 2019 to treat bladder tumor, cancer, neoplasm, urothelial carcinoma, and urinary bladder cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%balversa%" OR LOWER(tradeNames_string) LIKE "%balversa%" OR LOWER(drugSynonyms_string) LIKE "%balversa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5765', 'tradeNames_string': 'Balversa', 'drugName': 'Erdafitinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Urogenital Neoplasm (EFO_0003863), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Metastatic Prostate Cancer (EFO_0000196), Lymphoma (EFO_0000574), Urothelial Carcinoma (EFO_0008528), Squamous Cell Lung Carcinoma (EFO_0000708), Prostate Adenocarcinoma (EFO_0000673), Bladder Tumor (EFO_0000294)', 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.136 | Q22 | What is Trilipix? | Trilipix, also known generically as Choline Fenofibrate, was approved by the FDA in 2008 to treat cardiovascular disease. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trilipix%" OR LOWER(tradeNames_string) LIKE "%trilipix%" OR LOWER(drugSynonyms_string) LIKE "%trilipix%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_347', 'tradeNames_string': 'Fenocor-67, Fenogal, Fibricor, Lipanthyl, Lipofen, Lofibra, Supralip, Trilipix', 'drugName': 'Fenofibric Acid', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor alpha agonist', 'linkedDiseasesDrug_string': 'Hypertriglyceridemia (EFO_0004211), Coronary Artery Disease (EFO_0001645), Medulloblastoma (EFO_0002939), Combined Hyperlipidemia (Orphanet_79211), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Cholestasis (MONDO_0001751), Disorder Of Lipid Metabolism (Orphanet_309005), Type 2 Diabetes Mellitus (MONDO_0005148), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4196', 'tradeNames_string': 'Trilipix', 'drugName': 'Choline Fenofibrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor alpha agonist', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Combined Hyperlipidemia (Orphanet_79211), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Disorder Of Lipid Metabolism (Orphanet_309005)', 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.647 | Q22 | What is Xeljanz? | Xeljanz, also known generically as Tofacitinib Citrate, was approved by the FDA in 2012 to treat rheumatoid arthritis and psoriatic arthritis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xeljanz%" OR LOWER(tradeNames_string) LIKE "%xeljanz%" OR LOWER(drugSynonyms_string) LIKE "%xeljanz%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3515', 'tradeNames_string': 'Xeljanz, Xeljanz xr', 'drugName': 'Tofacitinib Citrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Janus Kinase (JAK) inhibitor', 'linkedDiseasesDrug_string': 'Discoid Lupus Erythematosus (MONDO_0019558), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685)', 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.139 | Q22 | What is Zetonna? | Zetonna, also known generically as Ciclesonide, was approved by the FDA in 2006 to treat Nasal congestion, Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zetonna%" OR LOWER(tradeNames_string) LIKE "%zetonna%" OR LOWER(drugSynonyms_string) LIKE "%zetonna%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4432', 'tradeNames_string': 'Alvesco, Alvesco 160, Alvesco 80, Omnaris, Zetonna', 'drugName': 'Ciclesonide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Rhinosinusitis (EFO_1000024), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Covid-19 (MONDO_0100096), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Allergic Disease (MONDO_0005271)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.112 | Q22 | What is Cabometyx? | Cabometyx, also known generically as Cabozantinib, was approved by the FDA in 2012 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cabometyx%" OR LOWER(tradeNames_string) LIKE "%cabometyx%" OR LOWER(drugSynonyms_string) LIKE "%cabometyx%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3579', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib S-Malate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3580', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib S-Malate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4806', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Intrahepatic Cholangiocarcinoma (EFO_1001961), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Neuroendocrine Carcinoma (MONDO_0002120), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Papillary Renal Cell Carcinoma (EFO_0000640), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Anaplastic Astrocytoma (EFO_0002499), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Endometrial Carcinoma (EFO_1001512), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Osteosarcoma (EFO_0000637), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Meningioma (MONDO_0016642), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4807', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Intrahepatic Cholangiocarcinoma (EFO_1001961), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Neuroendocrine Carcinoma (MONDO_0002120), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Papillary Renal Cell Carcinoma (EFO_0000640), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Anaplastic Astrocytoma (EFO_0002499), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Endometrial Carcinoma (EFO_1001512), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Osteosarcoma (EFO_0000637), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Meningioma (MONDO_0016642), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.184 | Q22 | What is Pristiq? | Pristiq, also known generically as Desvenlafaxine, was approved by the FDA in 2008 to treat unipolar depression, major depressive disorder, and depressive disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pristiq%" OR LOWER(tradeNames_string) LIKE "%pristiq%" OR LOWER(drugSynonyms_string) LIKE "%pristiq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1437', 'tradeNames_string': 'Desvenlafaxine, Khedezla, Pristiq', 'drugName': 'Desvenlafaxine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Chronic Hepatitis C Virus Infection (EFO_0004220), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1438', 'tradeNames_string': 'Desvenlafaxine, Khedezla, Pristiq', 'drugName': 'Desvenlafaxine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Chronic Hepatitis C Virus Infection (EFO_0004220), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_735', 'tradeNames_string': 'Desvenlafaxine succinate, Pristiq', 'drugName': 'Desvenlafaxine Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_736', 'tradeNames_string': 'Desvenlafaxine succinate, Pristiq', 'drugName': 'Desvenlafaxine Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.438 | Q22 | What is Morphabond Er? | Morphabond Er, also known generically as Morphine Sulfate, was approved by the FDA in 1984 to treat Chronic pain, cancer, pain, and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%morphabond er%" OR LOWER(tradeNames_string) LIKE "%morphabond er%" OR LOWER(drugSynonyms_string) LIKE "%morphabond er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3650', 'tradeNames_string': 'Arymo er, Astramorph pf, Avinza, Depodur, Duramorph, Duramorph pf, Duromorph, Filnarine sr, Infumorph, Kadian, Moraxen, Morcap sr, Morphabond, Morphabond er, Morphgesic sr, Morphine sulfate, Morphine sulfate (autoinjector), Ms contin, Mst continus, Oramorph, Oramorph sr, Oramorph udv, Rhotard, Sevredol, Srm-rhotard, Zomorph', 'drugName': 'Morphine Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Neonatal Abstinence Syndrome (EFO_0005799), Chronic Pain (HP_0012532), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616), Myocardial Infarction (EFO_0000612), Pulmonary Arterial Hypertension (EFO_0001361), Sickle Cell Anemia (MONDO_0011382), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419), Obstructive Sleep Apnea (EFO_0003918), Idiopathic Pulmonary Fibrosis (EFO_0000768), Pruritus (HP_0000989), Opioid Dependence (EFO_0005611)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.561 | Q22 | What is Naropin? | Naropin, also known generically as Ropivacaine Hydrochloride, was approved by the FDA in 1996 to treat pain. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naropin%" OR LOWER(tradeNames_string) LIKE "%naropin%" OR LOWER(drugSynonyms_string) LIKE "%naropin%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4841', 'tradeNames_string': 'Narapin, Naropin, Ropivacaine hydrochloride', 'drugName': 'Ropivacaine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Head And Neck Malignant Neoplasia (EFO_0006859), Bone Fracture (EFO_0003931), Osteoarthritis (MONDO_0005178), Inguinal Hernia (HP_0000023), Pain (EFO_0003843), Musculoskeletal System Disease (EFO_0009676)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.489 | Q22 | What is Oxycontin? | Oxycontin, also known generically as Oxycodone Hydrochloride, was approved by the FDA in 1950 to treat Chronic pain and pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxycontin%" OR LOWER(tradeNames_string) LIKE "%oxycontin%" OR LOWER(drugSynonyms_string) LIKE "%oxycontin%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6046', 'tradeNames_string': 'Oxycontin, Proladone, Xtampza er', 'drugName': 'Oxycodone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Cancer (MONDO_0004992), Genital Neoplasm, Female (EFO_1001331), Substance Abuse (MONDO_0002491), Pain (EFO_0003843), Injury (EFO_0000546), Colorectal Carcinoma (EFO_1001951), Nephrolithiasis (EFO_0004253), Spinal Cord Injury (EFO_1001919), Hypospadias (EFO_0004209), Preeclampsia (EFO_0000668), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Parkinson Disease (MONDO_0005180), Neuropathic Pain (EFO_0005762), Respiratory Depression (EFO_0009842), Pruritus (HP_0000989), Restless Legs Syndrome (EFO_0004270), Sinusitis (EFO_0007486), Nutritional Disorder (EFO_0001069), Neck Pain (HP_0030833), Drug Dependence (EFO_0003890), Diabetic Polyneuropathy (MONDO_0001583), Osteoarthritis, Hip (EFO_1000786), Back Pain (HP_0003418), Joint Disease (EFO_1000999), Opioid Dependence (EFO_0005611), Head And Neck Malignant Neoplasia (EFO_0006859), Opioid Use Disorder (EFO_0010702), Osteoarthritis (MONDO_0005178), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1950, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4049', 'tradeNames_string': 'Abtard, Candox, Carexil, Dolocodon pr, Leveraxo, Longtec, Lynlor, Oxaydo, Oxecta, Oxeltra, Oxycodone hydrochloride, Oxycontin, Oxylan, Oxynorm, Reltebon, Roxicodone, Roxybond, Shortec, Zomestine', 'drugName': 'Oxycodone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Osteoarthritis, Hip (EFO_1000786), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1950, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.523 | Q22 | What is Livalo? | Livalo, also known generically as Pitavastatin Calcium, was approved by the FDA in 2009 to treat Abnormal circulating lipid concentration and hyperlipidemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%livalo%" OR LOWER(tradeNames_string) LIKE "%livalo%" OR LOWER(drugSynonyms_string) LIKE "%livalo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_763', 'tradeNames_string': 'Livalo, Pitavastatin calcium', 'drugName': 'Pitavastatin Calcium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'HMG-CoA reductase inhibitor', 'linkedDiseasesDrug_string': 'Abnormal Circulating Lipid Concentration (HP_0003119), Hyperlipidemia (MONDO_0021187), Disorder Of Lipid Metabolism (Orphanet_309005), Hypercholesterolemia (HP_0003124)', 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.135 | Q22 | What is Clorotekal? | Clorotekal, also known generically as Chloroprocaine Hydrochloride, was approved by the FDA in 1955. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clorotekal%" OR LOWER(tradeNames_string) LIKE "%clorotekal%" OR LOWER(drugSynonyms_string) LIKE "%clorotekal%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2193', 'tradeNames_string': 'Ampres, Chloroprocaine hydrochloride, Clorotekal, Nesacaine, Nesacaine-mpf', 'drugName': 'Chloroprocaine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.179 | Q22 | What is Firmagon? | Firmagon, also known generically as Degarelix Acetate, was approved by the FDA in 2008 to treat prostate adenocarcinoma and prostate carcinoma. It is a protein therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%firmagon%" OR LOWER(tradeNames_string) LIKE "%firmagon%" OR LOWER(drugSynonyms_string) LIKE "%firmagon%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6054', 'tradeNames_string': 'Firmagon', 'drugName': 'Degarelix Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor antagonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1491', 'tradeNames_string': 'Firmagon', 'drugName': 'Degarelix', 'drugMolecularType': 'Protein', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor antagonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Benign Prostatic Hyperplasia (EFO_0000284), Covid-19 (MONDO_0100096), Prostate Neoplasm (MONDO_0021259), Male Breast Carcinoma (EFO_0006861), Metastatic Prostate Cancer (EFO_0000196), Infertility (EFO_0000545), Endometriosis (EFO_0001065), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.73 | Q22 | What is Qnasl? | Qnasl, also known generically as Beclomethasone Dipropionate, was approved by the FDA in 1976 to treat Nasal congestion, Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qnasl%" OR LOWER(tradeNames_string) LIKE "%qnasl%" OR LOWER(drugSynonyms_string) LIKE "%qnasl%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5013', 'tradeNames_string': 'Aerobec 100, Aerobec 50, Aerobec fte 250, Asmabec clickhaler, Asmabec spacehaler, Beclazone 100, Beclazone 100 e-breathe, Beclazone 200, Beclazone 250, Beclazone 250 e-breathe, Beclazone 50, Beclazone 50 e-breathe, Becloaqua 50, Becloforte, Becloforte e-breathe, Becloforte integra, Becloforte-vm, Beclomet diprop, Beclomet hayfever, Beclomist, Beclotaide, Beclovent, Becodisks, Beconase, Beconase aq, Becotide, Becotide 100, Becotide 100 e-breathe, Becotide 200, Becotide 50, Becotide 50 e-breathe, Clenil modulite, Clipper, Filair 100, Filair 50, Filair fte, Fostair, Fostair nexthaler, Nasobec aq, Nasobec hayfever, Propaderm, Propaderm fte, Propaderm-a, Propaderm-c, Pulvinal beclomet, Qnasl, Qvar 100, Qvar 100 e-breathe, Qvar 40, Qvar 50, Qvar 50 e-breathe, Qvar 80, Qvar redihaler, Rino clenil, Vancenase, Vancenase aq, Vancenase pockethaler, Vanceril, Vanceril double strength, Ventide, Vivabec, Zonivent aquanasal', 'drugName': 'Beclomethasone Dipropionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Allergic Rhinitis (EFO_0005854), Idiopathic Pulmonary Fibrosis (EFO_0000768), Seasonal Allergic Rhinitis (EFO_0003956), Acute Graft Vs. Host Disease (EFO_0004599), Nasal Cavity Polyp (EFO_1000391), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Small Cell Lung Carcinoma (EFO_0000702), Bronchiectasis (HP_0002110), Rhinitis, Allergic, Perennial (EFO_1001417), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Nasal Congestion (HP_0001742), Croup (EFO_0007227), Newborn Respiratory Distress Syndrome (EFO_1000644), Enteritis (MONDO_0043579), Folliculitis (EFO_1000702), Eosinophilic Esophagitis (EFO_0004232), Bronchopulmonary Dysplasia (MONDO_0019091)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1976, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.258 | Q22 | What is Subsys? | Subsys, also known generically as Fentanyl, was approved by the FDA in 1968 to treat Chronic pain, cancer, neoplasm, pain, and migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%subsys%" OR LOWER(tradeNames_string) LIKE "%subsys%" OR LOWER(drugSynonyms_string) LIKE "%subsys%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6302', 'tradeNames_string': 'Abstral, Actiq, Breakyl, Duragesic, Duragesic-100, Duragesic-12, Duragesic-25, Duragesic-37, Duragesic-50, Duragesic-75, Durogesic, Durogesic dtrans, Effentora, Fencino, Fentalis reservoir, Fentanyl-100, Fentanyl-12, Fentanyl-25, Fentanyl-37, Fentanyl-50, Fentanyl-62, Fentanyl-75, Fentanyl-87, Fentora, Ionsys, Leptanal, Matrifen, Mezolar matrix, Mylafent, Opiodur, Oralet, Osmach, Osmanil, Pecfent, Recivit, Sublimaze, Subsys, Tilofyl, Victanyl, Yemex', 'drugName': 'Fentanyl', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Liver Disease (EFO_0001421), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Migraine Disorder (MONDO_0005277), Irritable Bowel Syndrome (EFO_0000555), Injury (EFO_0000546), Hypotension (EFO_0005251), Pregnancy (EFO_0002950), Gastric Cancer (MONDO_0001056), Respiratory Insufficiency (HP_0002093), Hypospadias (EFO_0004209), Bronchospasm (HP_0025428), Breast Cancer (MONDO_0007254), Neuropathic Pain (EFO_0005762), Acute Respiratory Distress Syndrome (EFO_1000637), Scoliosis (EFO_0004273), Respiratory Depression (EFO_0009842), Interstitial Lung Disease (EFO_0004244), Morbid Obesity (EFO_0001074), Bone Fracture (EFO_0003931), Bone Metastasis (EFO_0009870), Pancreatic Carcinoma (EFO_0002618), Delirium (EFO_0009267), Subarachnoid Hemorrhage (EFO_0000713), Adenoma (EFO_0000232), Brain Injury (MONDO_0043510), Obstructive Sleep Apnea (EFO_0003918), Opioid Dependence (EFO_0005611), Shortness Of Breath (EFO_0009727), Dyspnea (HP_0002094), Chronic Kidney Disease (EFO_0003884), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Neoplasm (EFO_0000616), Diabetic Neuropathy (EFO_1000783), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Abscess (EFO_0003030), Aortic Coarctation (EFO_1001267)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1968, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.584 | Q22 | What is Januvia? | Januvia, also known generically as Sitagliptin, was approved by the FDA in 2006 to treat diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%januvia%" OR LOWER(tradeNames_string) LIKE "%januvia%" OR LOWER(drugSynonyms_string) LIKE "%januvia%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2411', 'tradeNames_string': 'Janumet Xr, Januvia', 'drugName': 'Sitagliptin Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dipeptidyl peptidase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Renal Insufficiency (HP_0000083), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3574', 'tradeNames_string': 'Januvia', 'drugName': 'Sitagliptin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dipeptidyl peptidase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Psoriasis (EFO_0000676), Hyperlipidemia (MONDO_0021187), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Hepatitis C Virus Infection (EFO_0003047), Hepatocellular Carcinoma (EFO_0000182), Congestive Heart Failure (EFO_0000373), Acute Myocardial Infarction (EFO_0008583), Diabetic Foot (EFO_1001459), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Glucose Intolerance (HP_0001952), Acute Graft Vs. Host Disease (EFO_0004599), Renal Insufficiency (HP_0000083), Abnormal Glucose Tolerance (EFO_0002546), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Hiv-1 Infection (EFO_0000180), Chronic Kidney Disease (EFO_0003884), Prediabetes Syndrome (EFO_1001121), Cystic Fibrosis (MONDO_0009061), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.656 | Q22 | What is Conzip? | Conzip, also known generically as Tramadol Hydrochloride, was approved by the FDA in 1995 to treat Chronic pain, pain, and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%conzip%" OR LOWER(tradeNames_string) LIKE "%conzip%" OR LOWER(drugSynonyms_string) LIKE "%conzip%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3268', 'tradeNames_string': 'Aceon, Conzip, Dromadol sr, Dromadol xl, Invodol sr, Larapam sr, Mabron, Maneo, Marol, Maxitram sr, Nobligan ret, Oldaram, Qdolo, Rybix odt, Ryzolt, Tilodol sr, Tradorec xl, Tramacet, Tramadol hydrochloride, Tramake, Tramake insts, Tramquel sr, Tramulief sr, Ultram, Ultram er, Zamadol, Zamadol 24hr, Zamadol melt, Zamadol sr, Zeridame sr, Zydol, Zydol sr, Zydol xl', 'drugName': 'Tramadol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Cancer (MONDO_0004992), Drug Dependence (EFO_0003890), Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.602 | Q22 | What is Zembrace Symtouch? | Zembrace Symtouch, also known generically as Sumatriptan Succinate, was approved by the FDA in 1992 to treat migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zembrace symtouch%" OR LOWER(tradeNames_string) LIKE "%zembrace symtouch%" OR LOWER(drugSynonyms_string) LIKE "%zembrace symtouch%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1609', 'tradeNames_string': 'Alsuma, Imigran, Imigran 50, Imigran radis, Imigran recovery, Imigran subject, Imitrex, Imitrex statdose, Migraitan, Migraleve ultra, Onzetra xsail, Sumatriptan succinate, Sumavel dosepro, Zecuity, Zembrace symtouch', 'drugName': 'Sumatriptan Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1d (5-HT1d) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Migraine With Aura (MONDO_0005475)', 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1610', 'tradeNames_string': 'Alsuma, Imigran, Imigran 50, Imigran radis, Imigran recovery, Imigran subject, Imitrex, Imitrex statdose, Migraitan, Migraleve ultra, Onzetra xsail, Sumatriptan succinate, Sumavel dosepro, Zecuity, Zembrace symtouch', 'drugName': 'Sumatriptan Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1b (5-HT1b) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Migraine With Aura (MONDO_0005475)', 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.673 | Q22 | What is Tukysa? | Tukysa, also known generically as Tucatinib, was approved by the FDA in 2020 to treat breast carcinoma, cancer, neoplasm, brain neoplasm, HER2 Positive Breast Carcinoma, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tukysa%" OR LOWER(tradeNames_string) LIKE "%tukysa%" OR LOWER(drugSynonyms_string) LIKE "%tukysa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5133', 'tradeNames_string': 'Tukysa', 'drugName': 'Tucatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-2 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616), Colorectal Neoplasm (EFO_0004142), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Triple-Negative Breast Cancer (EFO_0005537), Angiosarcoma (EFO_0003968), Brain Neoplasm (EFO_0003833), Her2 Positive Breast Carcinoma (EFO_1000294), Chronic Myelogenous Leukemia (EFO_0000339), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.358 | Q22 | What is Recorlev? | Recorlev, also known generically as Levoketoconazole, was approved by the FDA in 2021 to treat Cushing syndrome and adrenal gland hyperfunction. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%recorlev%" OR LOWER(tradeNames_string) LIKE "%recorlev%" OR LOWER(drugSynonyms_string) LIKE "%recorlev%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3929', 'tradeNames_string': 'Extina, Ketosidin, Ketozole, Nizoral, Nizoral A-D, Panfungol, Recorlev, Xolegel', 'drugName': 'Levoketoconazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cytochrome P450 11B1 inhibitor', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110), Type 2 Diabetes Mellitus (MONDO_0005148), Cushing Syndrome (EFO_0003099), Adrenal Gland Hyperfunction (EFO_1000797)", 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882), CYP11B2 (ENSG00000179142), CYP17A1 (ENSG00000148795), CYP11A1 (ENSG00000140459)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3930', 'tradeNames_string': 'Extina, Ketosidin, Ketozole, Nizoral, Nizoral A-D, Panfungol, Recorlev, Xolegel', 'drugName': 'Levoketoconazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cytochrome P450 11B2 inhibitor', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110), Type 2 Diabetes Mellitus (MONDO_0005148), Cushing Syndrome (EFO_0003099), Adrenal Gland Hyperfunction (EFO_1000797)", 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882), CYP11B2 (ENSG00000179142), CYP17A1 (ENSG00000148795), CYP11A1 (ENSG00000140459)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3931', 'tradeNames_string': 'Extina, Ketosidin, Ketozole, Nizoral, Nizoral A-D, Panfungol, Recorlev, Xolegel', 'drugName': 'Levoketoconazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cytochrome P450 11A1 inhibitor', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110), Type 2 Diabetes Mellitus (MONDO_0005148), Cushing Syndrome (EFO_0003099), Adrenal Gland Hyperfunction (EFO_1000797)", 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882), CYP11B2 (ENSG00000179142), CYP17A1 (ENSG00000148795), CYP11A1 (ENSG00000140459)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3932', 'tradeNames_string': 'Extina, Ketosidin, Ketozole, Nizoral, Nizoral A-D, Panfungol, Recorlev, Xolegel', 'drugName': 'Levoketoconazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cytochrome P450 17A1 inhibitor', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110), Type 2 Diabetes Mellitus (MONDO_0005148), Cushing Syndrome (EFO_0003099), Adrenal Gland Hyperfunction (EFO_1000797)", 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882), CYP11B2 (ENSG00000179142), CYP17A1 (ENSG00000148795), CYP11A1 (ENSG00000140459)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.77 | Q22 | What is Beleodaq? | Beleodaq, also known generically as Belinostat, was approved by the FDA in 2014 to treat unspecified peripheral T-cell lymphoma, cancer, neoplasm, mature T-cell and NK-cell non-Hodgkin lymphoma, and T-cell non-Hodgkin lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%beleodaq%" OR LOWER(tradeNames_string) LIKE "%beleodaq%" OR LOWER(drugSynonyms_string) LIKE "%beleodaq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1601', 'tradeNames_string': 'Beleodaq', 'drugName': 'Belinostat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Thymic Carcinoma (EFO_1000576), Anaplastic Large Cell Lymphoma (EFO_0003032), Urothelial Carcinoma (EFO_0008528), Burkitts Lymphoma (EFO_0000309), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Lymphoid Neoplasm (EFO_0001642), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Mycosis Fungoides (EFO_1001051), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Cutaneous T-Cell Lymphoma (EFO_0002913), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Thymoma (EFO_1000581), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Follicular Lymphoma (MONDO_0018906), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Adenocarcinoma (EFO_0000228), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.151 | Q22 | What is Cotellic? | Cotellic, also known generically as Cobimetinib, was approved by the FDA in 2015 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cotellic%" OR LOWER(tradeNames_string) LIKE "%cotellic%" OR LOWER(drugSynonyms_string) LIKE "%cotellic%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3656', 'tradeNames_string': 'Cotellic', 'drugName': 'Cobimetinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase 1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Cerebral Arteriovenous Malformation (Orphanet_46724), Skin Cancer (MONDO_0002898), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Gallbladder Carcinoma (EFO_1001956), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Skin Carcinoma (EFO_0009259), Craniopharyngioma (EFO_1000209), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756)', 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3657', 'tradeNames_string': 'Cotellic', 'drugName': 'Cobimetinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase 2 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Cerebral Arteriovenous Malformation (Orphanet_46724), Skin Cancer (MONDO_0002898), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Gallbladder Carcinoma (EFO_1001956), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Skin Carcinoma (EFO_0009259), Craniopharyngioma (EFO_1000209), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756)', 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6004', 'tradeNames_string': 'Cotellic', 'drugName': 'Cobimetinib Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase 1 inhibitor', 'linkedDiseasesDrug_string': 'Metastatic Melanoma (EFO_0002617)', 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6005', 'tradeNames_string': 'Cotellic', 'drugName': 'Cobimetinib Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase 2 inhibitor', 'linkedDiseasesDrug_string': 'Metastatic Melanoma (EFO_0002617)', 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.352 | Q22 | What is Elepsia Xr? | Elepsia Xr, also known generically as Levetiracetam, was approved by the FDA in 1999 to treat Seizure, Bilateral tonic-clonic seizure, Focal-onset seizure, epilepsy, and epilepsy with generalized tonic-clonic seizures. It is a small molecule therapy that acts as a(n) modulator and blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%elepsia xr%" OR LOWER(tradeNames_string) LIKE "%elepsia xr%" OR LOWER(drugSynonyms_string) LIKE "%elepsia xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_283', 'tradeNames_string': 'Desitrend, Elepsia xr, Keppra, Keppra xr, Levetiracetam, Levetiracetam in sodium chloride, Matever, Spritam', 'drugName': 'Levetiracetam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Synaptic vesicle glycoprotein 2A modulator', 'linkedDiseasesDrug_string': 'Canavan Disease (MONDO_0010079), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Movement Disorder (EFO_0004280), Focal-Onset Seizure (HP_0007359), Central Nervous System Cancer (EFO_0000326), Panic Disorder (EFO_0004262), Status Epilepticus (EFO_0008526), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Aphasia (HP_0002381), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Photosensitive Epilepsy (MONDO_0015643), Seizure (HP_0001250), Acute Myeloid Leukemia (EFO_0000222), Alcohol Withdrawal (EFO_0004777), Restless Legs Syndrome (EFO_0004270), Obsessive-Compulsive Disorder (EFO_0004242), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Subarachnoid Hemorrhage (EFO_0000713), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Postherpetic Neuralgia (MONDO_0041052), Torticollis (HP_0000473), Polyneuropathy (EFO_0009562), Generalized Non-Motor (Absence) Seizure (HP_0002121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408), SV2A (ENSG00000159164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_284', 'tradeNames_string': 'Desitrend, Elepsia xr, Keppra, Keppra xr, Levetiracetam, Levetiracetam in sodium chloride, Matever, Spritam', 'drugName': 'Levetiracetam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated N-type calcium channel alpha-1B subunit blocker', 'linkedDiseasesDrug_string': 'Canavan Disease (MONDO_0010079), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Movement Disorder (EFO_0004280), Focal-Onset Seizure (HP_0007359), Central Nervous System Cancer (EFO_0000326), Panic Disorder (EFO_0004262), Status Epilepticus (EFO_0008526), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Aphasia (HP_0002381), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Photosensitive Epilepsy (MONDO_0015643), Seizure (HP_0001250), Acute Myeloid Leukemia (EFO_0000222), Alcohol Withdrawal (EFO_0004777), Restless Legs Syndrome (EFO_0004270), Obsessive-Compulsive Disorder (EFO_0004242), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Subarachnoid Hemorrhage (EFO_0000713), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Postherpetic Neuralgia (MONDO_0041052), Torticollis (HP_0000473), Polyneuropathy (EFO_0009562), Generalized Non-Motor (Absence) Seizure (HP_0002121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408), SV2A (ENSG00000159164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.93 | Q22 | What is Vyleesi (Autoinjector)? | Vyleesi (Autoinjector), also known generically as Bremelanotide Acetate, was approved by the FDA in 2019 to treat mental or behavioural disorder and sexual dysfunction. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vyleesi (autoinjector)%" OR LOWER(tradeNames_string) LIKE "%vyleesi (autoinjector)%" OR LOWER(drugSynonyms_string) LIKE "%vyleesi (autoinjector)%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_177', 'tradeNames_string': 'Vyleesi (autoinjector)', 'drugName': 'Bremelanotide Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Melanocortin receptor 4 agonist', 'linkedDiseasesDrug_string': 'Sexual Dysfunction (EFO_0004714), Mental Or Behavioural Disorder (EFO_0000677)', 'newLinkedTargets_string': 'MC4R (ENSG00000166603)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.688 | Q22 | What is Gemtesa? | Gemtesa, also known generically as Vibegron, was approved by the FDA in 2020 to treat Urinary incontinence, urgency urinary incontinence, and overactive bladder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gemtesa%" OR LOWER(tradeNames_string) LIKE "%gemtesa%" OR LOWER(drugSynonyms_string) LIKE "%gemtesa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_9', 'tradeNames_string': 'Gemtesa', 'drugName': 'Vibegron', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-3 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Overactive Bladder (EFO_1000781), Hypertension (EFO_0000537), Irritable Bowel Syndrome (EFO_0000555), Urinary Incontinence (HP_0000020)', 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.11 | Q22 | What is Gilotrif? | Gilotrif, also known generically as Afatinib Dimaleate, was approved by the FDA in 2013 to treat non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gilotrif%" OR LOWER(tradeNames_string) LIKE "%gilotrif%" OR LOWER(drugSynonyms_string) LIKE "%gilotrif%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1042', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugName': 'Afatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor erbB1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gallbladder Carcinoma (EFO_1001956), Endometriosis (EFO_0001065), Renal Insufficiency (HP_0000083), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Lung Neoplasm (MONDO_0021117), Glioma (EFO_0005543), Brain Cancer (MONDO_0001657), Metastatic Neoplasm (EFO_0009709), Urogenital Neoplasm (EFO_0003863), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1043', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugName': 'Afatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-2 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gallbladder Carcinoma (EFO_1001956), Endometriosis (EFO_0001065), Renal Insufficiency (HP_0000083), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Lung Neoplasm (MONDO_0021117), Glioma (EFO_0005543), Brain Cancer (MONDO_0001657), Metastatic Neoplasm (EFO_0009709), Urogenital Neoplasm (EFO_0003863), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1044', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugName': 'Afatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-4 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gallbladder Carcinoma (EFO_1001956), Endometriosis (EFO_0001065), Renal Insufficiency (HP_0000083), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Lung Neoplasm (MONDO_0021117), Glioma (EFO_0005543), Brain Cancer (MONDO_0001657), Metastatic Neoplasm (EFO_0009709), Urogenital Neoplasm (EFO_0003863), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2558', 'tradeNames_string': 'Gilotrif', 'drugName': 'Afatinib Dimaleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor erbB1 inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2559', 'tradeNames_string': 'Gilotrif', 'drugName': 'Afatinib Dimaleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-2 inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2560', 'tradeNames_string': 'Gilotrif', 'drugName': 'Afatinib Dimaleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-4 inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.64 | Q22 | What is Children'S Astepro Allergy? | Children'S Astepro Allergy, also known generically as Azelastine Hydrochloride, was approved by the FDA in 1996 to treat Nasal congestion, seasonal allergic rhinitis, allergic rhinitis, allergic conjunctivitis, vasomotor rhinitis, and Rhinitis, Allergic, Perennial. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%children's astepro allergy%" OR LOWER(tradeNames_string) LIKE "%children's astepro allergy%" OR LOWER(drugSynonyms_string) LIKE "%children's astepro allergy%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3567', 'tradeNames_string': "Astelin, Astepro, Astepro allergy, Azelastine hydrochloride, Children's astepro allergy, Optilast, Optivar, Rhinolast, Rhinolast allergy", 'drugName': 'Azelastine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Non-Allergic Rhinitis (EFO_0009364), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.642 | Q22 | What is Klisyri? | Klisyri, also known generically as Tirbanibulin, was approved by the FDA in 2020 to treat actinic keratosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%klisyri%" OR LOWER(tradeNames_string) LIKE "%klisyri%" OR LOWER(drugSynonyms_string) LIKE "%klisyri%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5805', 'tradeNames_string': 'Klisyri', 'drugName': 'Tirbanibulin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase SRC inhibitor', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Prostate Cancer (MONDO_0008315), Actinic Keratosis (EFO_0002496), Lymphoma (EFO_0000574)', 'newLinkedTargets_string': 'SRC (ENSG00000197122)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.663 | Q22 | What is Desyrel? | Desyrel, also known generically as Trazodone Hydrochloride, was approved by the FDA in 1981 to treat unipolar depression, major depressive disorder, and depressive disorder. It is a small molecule therapy that acts as a(n) inhibitor and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desyrel%" OR LOWER(tradeNames_string) LIKE "%desyrel%" OR LOWER(drugSynonyms_string) LIKE "%desyrel%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4975', 'tradeNames_string': 'Desyrel, Molipaxin, Molipaxin cr, Oleptro, Trazodone hydrochloride, Trialodine', 'drugName': 'Trazodone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1981, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4976', 'tradeNames_string': 'Desyrel, Molipaxin, Molipaxin cr, Oleptro, Trazodone hydrochloride, Trialodine', 'drugName': 'Trazodone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2c (5-HT2c) receptor antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1981, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4977', 'tradeNames_string': 'Desyrel, Molipaxin, Molipaxin cr, Oleptro, Trazodone hydrochloride, Trialodine', 'drugName': 'Trazodone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1981, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1291', 'tradeNames_string': '', 'drugName': 'Trazodone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Unipolar Depression (EFO_0003761), Postpartum Depression (EFO_0007453), Sleep Disorder (EFO_0008568), Diabetic Neuropathy (EFO_1000783), Amyotrophic Lateral Sclerosis (MONDO_0004976), Dementia (HP_0000726), Anxiety (EFO_0005230), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Obstructive Sleep Apnea (EFO_0003918), Insomnia (EFO_0004698), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1981, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1292', 'tradeNames_string': '', 'drugName': 'Trazodone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2c (5-HT2c) receptor antagonist', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Unipolar Depression (EFO_0003761), Postpartum Depression (EFO_0007453), Sleep Disorder (EFO_0008568), Diabetic Neuropathy (EFO_1000783), Amyotrophic Lateral Sclerosis (MONDO_0004976), Dementia (HP_0000726), Anxiety (EFO_0005230), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Obstructive Sleep Apnea (EFO_0003918), Insomnia (EFO_0004698), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1981, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1293', 'tradeNames_string': '', 'drugName': 'Trazodone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Unipolar Depression (EFO_0003761), Postpartum Depression (EFO_0007453), Sleep Disorder (EFO_0008568), Diabetic Neuropathy (EFO_1000783), Amyotrophic Lateral Sclerosis (MONDO_0004976), Dementia (HP_0000726), Anxiety (EFO_0005230), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Obstructive Sleep Apnea (EFO_0003918), Insomnia (EFO_0004698), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1981, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.177 | Q22 | What is Defitelio? | Defitelio, also known generically as Defibrotide Sodium, was approved by the FDA in 2016 to treat hepatic veno-occlusive disease. It is a oligonucleotide therapy that acts as a(n) activator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%defitelio%" OR LOWER(tradeNames_string) LIKE "%defitelio%" OR LOWER(drugSynonyms_string) LIKE "%defitelio%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_826', 'tradeNames_string': 'Defitelio', 'drugName': 'Defibrotide Sodium', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'activator', 'drugMechanismOfAction': 'Plasminogen activator', 'linkedDiseasesDrug_string': 'Hepatic Veno-Occlusive Disease (MONDO_0019514)', 'newLinkedTargets_string': 'PLG (ENSG00000122194)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2016, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.260 | Q22 | What is Lazanda? | Lazanda, also known generically as Fentanyl Citrate, was approved by the FDA in 1968 to treat cancer and pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lazanda%" OR LOWER(tradeNames_string) LIKE "%lazanda%" OR LOWER(drugSynonyms_string) LIKE "%lazanda%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_733', 'tradeNames_string': 'Abstral, Actiq, Fentanyl, Fentanyl citrate, Fentanyl citrate preservative free, Fentora, Lazanda, Onsolis, Sublimaze, Sublimaze preservative free, Thalamonal', 'drugName': 'Fentanyl Citrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Shortness Of Breath (EFO_0009727), Cancer (MONDO_0004992), Dyspnea (HP_0002094), Pulpitis (EFO_1001139), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Interstitial Lung Disease (EFO_0004244), Low Back Pain (HP_0003419), Injury (EFO_0000546)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1968, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.674 | Q22 | What is Ubrelvy? | Ubrelvy, also known generically as Ubrogepant, was approved by the FDA in 2019 to treat migraine disorder. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ubrelvy%" OR LOWER(tradeNames_string) LIKE "%ubrelvy%" OR LOWER(drugSynonyms_string) LIKE "%ubrelvy%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_528', 'tradeNames_string': 'Ubrelvy', 'drugName': 'Ubrogepant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Calcitonin gene-related peptide type 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'newLinkedTargets_string': 'CALCRL (ENSG00000064989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.32 | Q22 | What is Nexterone? | Nexterone, also known generically as Amiodarone Hydrochloride, was approved by the FDA in 1985 to treat Ventricular arrhythmia, ventricular fibrillation, and ventricular tachycardia. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nexterone%" OR LOWER(tradeNames_string) LIKE "%nexterone%" OR LOWER(drugSynonyms_string) LIKE "%nexterone%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3146', 'tradeNames_string': 'Amidox, Amiodarone hydrochloride, Amyben, Cordarone, Cordarone x, Cordarone x 100, Cordarone x 200, Darmil, Nexterone, Pacerone', 'drugName': 'Amiodarone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'HERG blocker', 'linkedDiseasesDrug_string': 'Ventricular Tachycardia (EFO_0005306), Atrial Fibrillation (EFO_0000275), Al Amyloidosis (MONDO_0019438), Heart Failure (EFO_0003144), Ventricular Fibrillation (EFO_0004287), Ventricular Arrhythmia (HP_0004308), Chagas Cardiomyopathy (EFO_0005529)', 'newLinkedTargets_string': 'KCNH2 (ENSG00000055118)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.375 | Q22 | What is Linzess? | Linzess, also known generically as Linaclotide, was approved by the FDA in 2012 to treat Constipation, irritable bowel syndrome, and constipation disorder. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%linzess%" OR LOWER(tradeNames_string) LIKE "%linzess%" OR LOWER(drugSynonyms_string) LIKE "%linzess%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5063', 'tradeNames_string': 'Constella, Linzess', 'drugName': 'Linaclotide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Heat-stable enterotoxin receptor agonist', 'linkedDiseasesDrug_string': 'Colorectal Adenoma (EFO_0005406), Constipation (HP_0002019), Constipation Disorder (MONDO_0002203), Irritable Bowel Syndrome (EFO_0000555), Colorectal Carcinoma (EFO_1001951)', 'newLinkedTargets_string': 'GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.577 | Q22 | What is Ozempic? | Ozempic, also known generically as Semaglutide, was approved by the FDA in 2017 to treat diabetes mellitus and type 2 diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ozempic%" OR LOWER(tradeNames_string) LIKE "%ozempic%" OR LOWER(drugSynonyms_string) LIKE "%ozempic%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6086', 'tradeNames_string': 'Ozempic, Rybelsus, Wegovy', 'drugName': 'Semaglutide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon-like peptide 1 receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Osteopenia (HP_0000938), Alzheimer Disease (MONDO_0004975), Asthma (MONDO_0004979), Coronary Artery Disease (EFO_0001645), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249), Parkinson Disease (MONDO_0005180), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Major Depressive Disorder (MONDO_0002009), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.79 | Q22 | What is Welireg? | Welireg, also known generically as Belzutifan, was approved by the FDA in 2021 to treat clear cell renal carcinoma, neoplasm, renal cell carcinoma, pancreatic neuroendocrine tumor, von Hippel-Lindau disease, and hemangioblastoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%welireg%" OR LOWER(tradeNames_string) LIKE "%welireg%" OR LOWER(drugSynonyms_string) LIKE "%welireg%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_342', 'tradeNames_string': 'Welireg', 'drugName': 'Belzutifan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Endothelial PAS domain-containing protein 1 inhibitor', 'linkedDiseasesDrug_string': 'Hemangioblastoma (MONDO_0016748), Chronic Kidney Disease (EFO_0003884), Pancreatic Neuroendocrine Tumor (EFO_1000045), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Von Hippel-Lindau Disease (MONDO_0008667)', 'newLinkedTargets_string': 'EPAS1 (ENSG00000116016)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.539 | Q22 | What is Doral? | Doral, also known generically as Quazepam, was approved by the FDA in 1985 to treat insomnia. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%doral%" OR LOWER(tradeNames_string) LIKE "%doral%" OR LOWER(drugSynonyms_string) LIKE "%doral%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4794', 'tradeNames_string': '', 'drugName': 'Avdoralimab', 'drugMolecularType': 'Antibody', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'C5a anaphylatoxin chemotactic receptor inhibitor', 'linkedDiseasesDrug_string': 'Covid-19 (MONDO_0100096), Bullous Pemphigoid (EFO_0007187), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'C5AR1 (ENSG00000197405)', 'maxClinicalTrialPhase': 2, 'yearOfFirstApproval': 0, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_3979', 'tradeNames_string': 'Doral', 'drugName': 'Quazepam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'GABA-A receptor; anion channel positive allosteric modulator', 'linkedDiseasesDrug_string': 'Insomnia (EFO_0004698)', 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.555 | Q22 | What is Atelvia? | Atelvia, also known generically as Risedronate Sodium, was approved by the FDA in 1998 to treat postmenopausal osteoporosis, osteoporosis, and Paget disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atelvia%" OR LOWER(tradeNames_string) LIKE "%atelvia%" OR LOWER(drugSynonyms_string) LIKE "%atelvia%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4717', 'tradeNames_string': 'Actonel, Atelvia, Risedronate sodium', 'drugName': 'Risedronate Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Farnesyl diphosphate synthase inhibitor', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Paget Disease (MONDO_0021165), Postmenopausal Osteoporosis (EFO_0003854), Leukemia (EFO_0000565), Lymphoma (EFO_0000574), Anorexia Nervosa (MONDO_0005351), Osteogenesis Imperfecta (MONDO_0019019)', 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.215 | Q22 | What is Promacta? | Promacta, also known generically as Eltrombopag Olamine, was approved by the FDA in 2008 to treat Thrombocytopenia, chronic hepatitis C virus infection, severe aplastic anemia, and autoimmune thrombocytopenic purpura. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%promacta%" OR LOWER(tradeNames_string) LIKE "%promacta%" OR LOWER(drugSynonyms_string) LIKE "%promacta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2769', 'tradeNames_string': 'Promacta, Promacta kit', 'drugName': 'Eltrombopag Olamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thrombopoietin receptor agonist', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Severe Aplastic Anemia (EFO_0006927), Chronic Hepatitis C Virus Infection (EFO_0004220), Myelodysplastic Syndrome (EFO_0000198)', 'newLinkedTargets_string': 'MPL (ENSG00000117400)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.56 | Q22 | What is Tavneos? | Tavneos, also known generically as Avacopan, was approved by the FDA in 2021 to treat anti-neutrophil antibody associated vasculitis, Granulomatosis with Polyangiitis, microscopic polyangiitis, and Anti-neutrophil cytoplasmic antibody-associated vasculitis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tavneos%" OR LOWER(tradeNames_string) LIKE "%tavneos%" OR LOWER(drugSynonyms_string) LIKE "%tavneos%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5921', 'tradeNames_string': 'Tavneos', 'drugName': 'Avacopan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'C5a anaphylatoxin chemotactic receptor antagonist', 'linkedDiseasesDrug_string': 'Microscopic Polyangiitis (EFO_1000784), Atypical Hemolytic-Uremic Syndrome (MONDO_0016244), Vasculitis (EFO_0006803), Iga Glomerulonephritis (EFO_0004194), Granulomatosis With Polyangiitis (EFO_0005297), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (MONDO_0015492), Hidradenitis Suppurativa (EFO_1000710), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826)', 'newLinkedTargets_string': 'C5AR1 (ENSG00000197405)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.138 | Q22 | What is Omnaris? | Omnaris, also known generically as Ciclesonide, was approved by the FDA in 2006 to treat Nasal congestion, Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%omnaris%" OR LOWER(tradeNames_string) LIKE "%omnaris%" OR LOWER(drugSynonyms_string) LIKE "%omnaris%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4432', 'tradeNames_string': 'Alvesco, Alvesco 160, Alvesco 80, Omnaris, Zetonna', 'drugName': 'Ciclesonide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Rhinosinusitis (EFO_1000024), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Covid-19 (MONDO_0100096), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Allergic Disease (MONDO_0005271)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.